Severe eosinophilic asthma awareness is on the rise, but a new GSK/Harris Poll survey reveals gaps for docs and patients, says GSK senior medical lead.
People with certain chronic conditions are faring worse than others during the pandemic. A new survey from The Harris Poll commissioned by GlaxoSmithKline finds that people with asthma, specifically severe eosinophilic asthma, are among them.
More than two-thirds (68%) of patients diagnosed with severe eosinophilic asthma surveyed describe their health as fair or poor – and that may be downplaying the reality. Ninety percent of physicians who see severe asthma patients surveyed rate their patients’ overall quality of life using the same fair or poor descriptors.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
KEY POINTS
Patients prefer oral dosing, but swallowing tablets can be a challenge for many patients. The Zydis® orally disintegrating tablet (ODT) platform addresses challenges associated with oral dosing, expanding benefits for patients and options for healthcare providers. A strong growth trajectory is expected for ODTs given therapeutic innovation and continued technology development.
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing or sucking, offer a patient-friendly dosage form for the administration of small-molecule drugs, peptides and proteins. With the potential for multiple sites of drug absorption, often faster onset action for the active pharmaceutical ingredient (API), and potentially greater bioavailability, ODTs are an attractive option for drug developers considering first-to-market formulations or product line extensions of existing drugs with compatible API. In this report, we look at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.
Please signup to continue — it’s fast and free. This article is sponsored by Catalent and produced by Endpoints Studio. Even though many biopharma leaders have come together in recent years to address its gender gap, the consensus is clear: We still have a long way to go.
Companies this year were 2.5 times more likely than last year to have a diversity and inclusion program in place, according to a recent BIO survey, but women are still largely absent from executive roles. Getting women to enter the industry isn’t the problem — studies show that they represent just under half of all biotech employees around the world. But climbing through the ranks can be challenging, as women still report facing stereotypes, and, unfortunately, harassment.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
Each year, we aim to highlight 20 extraordinary women who are leaving their mark on drug R&D — and this year’s group was no exception.
Our list, while by no means exhaustive, includes scientists, CEOs, researchers and professors who are supercharging the discovery and development of new therapies worldwide. Our team of writers spent time with each honoree (with a few exceptions), learning their stories and sketching profiles, which you’ll find in our special report.
For the second time, we brought the celebration to a live virtual audience, featuring an award presentation followed by a panel on what it takes to break the glass ceiling in biopharma with Kojin Therapeutics CEO Luba Greenwood, AskBio CEO Sheila Mikhail, and Silverback Therapeutics CEO Laura Shawver. Our panelists had a lively discussion on how the industry’s culture has changed, how to handle sexual harassment, the progress we’ve made and the challenges that still hold women back today.
We applaud each of our honorees for scaling the heights of biopharma R&D. You got to meet most of them via brief recordings we played during our live event. Below, you’ll find bonus videos offering a longer glimpse into those interviews. And if you didn’t get a chance to tune in to our main event live, you can replay the entire show.
Unlock this article along with other benefits by subscribing to one of our paid plans.
Members of the public disembark a train at King Cross Station in London, on the day that extra measures are put in place to fight the spread of the Omicron variant of Covid-19. Since Nov. 30, it’s been mandatory for people in England to wear face coverings in shops and on public transport. (Ben Cawthra/Sipa USA/Sipa via AP Images)
Like hundreds of other virologists and epidemiologists, Benjamin tenOever’s Thanksgiving weekend was interrupted with emails about an emergency Omicron meeting.
But when he logged onto a WHO conference call 9 a.m. Monday morning, officials had a surprisingly upbeat spin on the little-understood variant that had already prompted leaders around the world, fearful the strain could evade vaccines, to close their borders to broad swaths of Southern Africa.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
Viatris (Mylan/Pfizer’s Upjohn) and India’s Biocon Biologics are reportedly pondering whether to further entwine their biosimilar businesses into a $10 billion standalone company, according to sources from Nisha Poddar at an Indian affiliate of CNBC.
Earlier this summer, the two companies won the first highly-coveted interchangeability designation for their biosimilar Semglee, which is an insulin that’s interchangeable with Sanofi’s Lantus. Although, in a bizarre twist with the way the US insulin market works, the companies had to launch two versions of the interchangeable — one at a 65% discount, and one at a much higher price in order to gain market share.
Myelodysplastic syndrome is not only hard to say, it’s also hard to explain. So Novartis hired Noma Bar, an artist and illustrator well-known for his simple and striking imagery to create a video that explains the rare blood cancer.
The 2-minute video uses bold colors and seamless graphics that morph from image to image. A white blood cell, for instance, turns into a Pacman-like character gobbling infection, while a drop of blood turns into a dial pointer and then an exclamation point.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
The newest building at Fujifilm Irvine Scientific’s Netherlands campus is open for business.
The company, amidst a massive amount of expansion that has placed it in the top-five companies by manufacturing capacity, announced the Tilburg site is fully operational as of Wednesday. It will allow for an increase in efficiency and affordability in shipping, thanks to its central Europe location, as well as put some flexibility into the supply chain.
Unlock this story instantly and join 125,300+ biopharma pros reading Endpoints daily — and it’s free.
Uğur Şahin, BioNTech CEO (Frank Rumpenhorst/dpa via AP Images)
Moderna and Pfizer-BioNTech are now racing to develop Omicron-specific boosters, hoping to be ready if the new immune-evasive variant becomes dominant globally. But it wasn’t always clear that variant boosters could even work.
After the first Covid-19 vaccines were authorized and talk began of variants and next-generation vaccines, several vaccinologists raised concerns in the media and the scientific press about a potentially deleterious phenomenon that sounds as if it were born out of the Vatican’s immunology wing: Original antigenic sin.
Martin Shkreli (AP Images)
The Federal Trade Commission and seven states on Tuesday announced a new order under which the states will recoup $40 million from pharma badboy Martin Shkreli, who’s currently in prison for securities fraud, and who spiked the price of an old, cheap toxoplasmosis drug Daraprim by 4,000% overnight.
The order follows a January 2020 complaint against Shkreli, his associate Kevin Mulleady, who’s banned from working in for pharma for 7 years, their company Vyera Pharmaceuticals and its parent company Phoenixus AG. The complaint alleged that Shkreli and Mulleady not only hiked the price of Daraprim but used restrictive distribution and supply agreements, as well as data secrecy, to illegally block cheaper generic versions of the drug.
https://endpts.com/glaxosmithkline-enlisted-harris-poll-for-a-severe-asthma-survey-results-point-to-more-outreach/
